Literature DB >> 10676822

The pharmacokinetics of etanercept in healthy volunteers.

J M Korth-Bradley1, A S Rubin, R K Hanna, D K Simcoe, M E Lebsack.   

Abstract

OBJECTIVE: To describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers.
METHODS: Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations.
RESULTS: Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/-98 mg x h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours.
CONCLUSIONS: Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.

Mesh:

Substances:

Year:  2000        PMID: 10676822     DOI: 10.1345/aph.19126

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  35 in total

1.  The pharmacokinetics of etanercept in patients with heart failure.

Authors:  O Soran; A M Feldman; V M Schneider; R Hanna; D L Mann; J M Korth-Bradley
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Immunomodulatory drugs regulate HMGB1 release from activated human monocytes.

Authors:  Hanna Schierbeck; Heidi Wähämaa; Ulf Andersson; Helena Erlandsson Harris
Journal:  Mol Med       Date:  2010-04-09       Impact factor: 6.354

4.  Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis.

Authors:  Ivan Nestorov; Ralph Zitnik; Thomas Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745

Review 5.  Evidence of effectiveness: how much can we extrapolate from existing studies?

Authors:  Howard Lee; Dong-Seok Yim; Honghui Zhou; Carl C Peck
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

6.  Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.

Authors:  Ivan Nestorov; Ralph Zitnik; Todd DeVries; Arline M Nakanishi; Andrea Wang; Christopher Banfield
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

7.  Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats.

Authors:  Xi Chen; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2015-04-01       Impact factor: 3.922

8.  Pharmacokinetics and immunogenicity of T0001, a newly developed anti-TNFα fusion protein, in healthy volunteers.

Authors:  Yitong Wang; Chang Liu; Shi Chen; Wei Wang; Lihou Dong; Qian Wang; Yan Wang; Libo Zhao; Yannan Zang; Zhenwei Xie; Yang Liu; Yanjun Liu; Haifeng Song; Zhanguo Li; Yi Fang
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

Review 9.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

10.  Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.

Authors:  Bruce Kirkham; Khaldoun Chaabo; Christopher Hall; Toby Garrood; Timothy Mant; Elizabeth Allen; Alexandra Vincent; Joana C Vasconcelos; Andrew T Prevost; Gabriel S Panayi; Valerie M Corrigall
Journal:  Rheumatology (Oxford)       Date:  2016-08-07       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.